JP2012522748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522748A5 JP2012522748A5 JP2012502648A JP2012502648A JP2012522748A5 JP 2012522748 A5 JP2012522748 A5 JP 2012522748A5 JP 2012502648 A JP2012502648 A JP 2012502648A JP 2012502648 A JP2012502648 A JP 2012502648A JP 2012522748 A5 JP2012522748 A5 JP 2012522748A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- carboxamide
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 22
- -1 cyano, hydroxy Chemical group 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 4
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000055981 human SCD1 Human genes 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- YUQNMSHQHNXGBK-UHFFFAOYSA-N 4-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=C(Cl)C=CC=C4C3)CC2)=C1 YUQNMSHQHNXGBK-UHFFFAOYSA-N 0.000 claims 1
- KUGGGESSHFFBEL-UHFFFAOYSA-N 5-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=C(Cl)C=CC=C2CC3)=C1 KUGGGESSHFFBEL-UHFFFAOYSA-N 0.000 claims 1
- PHYZSAULJWQSEQ-UHFFFAOYSA-N 5-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=CC(F)=CC=C4C3)CC2)=C1 PHYZSAULJWQSEQ-UHFFFAOYSA-N 0.000 claims 1
- FUHJCGFYGGUCJX-UHFFFAOYSA-N 5-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC=C(F)C=C4C3)CC2)=C1 FUHJCGFYGGUCJX-UHFFFAOYSA-N 0.000 claims 1
- HGVXTAGDJKVCDK-UHFFFAOYSA-N 6-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC(F)=CC=C2CC3)=C1 HGVXTAGDJKVCDK-UHFFFAOYSA-N 0.000 claims 1
- HYDIUJYJUOWWLE-UHFFFAOYSA-N 6-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC(F)=CC=C4C3)CC2)=C1 HYDIUJYJUOWWLE-UHFFFAOYSA-N 0.000 claims 1
- YGBGLDFQYNRHAV-UHFFFAOYSA-N 6-fluoro-n-[4-[(1-methylpyrazol-4-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound C1=NN(C)C=C1CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=C(F)C=C2CC3)=C1 YGBGLDFQYNRHAV-UHFFFAOYSA-N 0.000 claims 1
- DVDORZHPBMOJAU-UHFFFAOYSA-N 6-fluoro-n-[4-[(5-methyl-1,2-oxazol-3-yl)methylcarbamoyl]pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound O1C(C)=CC(CNC(=O)C=2C=C(NC(=O)N3CCC4(CC3)OC3=CC=C(F)C=C3CC4)N=CC=2)=N1 DVDORZHPBMOJAU-UHFFFAOYSA-N 0.000 claims 1
- OLYSEANEZKWQPH-UHFFFAOYSA-N 7-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=C(Cl)C=CC=C4C3)CC2)=C1 OLYSEANEZKWQPH-UHFFFAOYSA-N 0.000 claims 1
- CEPSJAIIFPRILD-UHFFFAOYSA-N 7-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC(F)=CC=C2C(=O)C3)=C1 CEPSJAIIFPRILD-UHFFFAOYSA-N 0.000 claims 1
- QTWOGSMPWCVSNE-UHFFFAOYSA-N 7-fluoro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC=C(F)C=C2CC3)=C1 QTWOGSMPWCVSNE-UHFFFAOYSA-N 0.000 claims 1
- RZAAQIJYIQVPLL-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]-4-oxospiro[3h-chromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2C(=O)C3)=C1 RZAAQIJYIQVPLL-UHFFFAOYSA-N 0.000 claims 1
- XSOMTMVYQGTMOC-UHFFFAOYSA-N 8-chloro-n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=C(Cl)C=CC=C2CC3)=C1 XSOMTMVYQGTMOC-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010027525 Microalbuminuria Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 102000018692 Sulfonylurea Receptors Human genes 0.000 claims 1
- 108010091821 Sulfonylurea Receptors Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 230000002473 insulinotropic effect Effects 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- IHROGSPCAYGOHJ-UHFFFAOYSA-N n-(4-carbamoylpyridin-2-yl)-6-fluorospiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound NC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=C(F)C=C2CC3)=C1 IHROGSPCAYGOHJ-UHFFFAOYSA-N 0.000 claims 1
- GPPQSKJCIMSNHA-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC4=CC=CC=C4C3)CC2)=C1 GPPQSKJCIMSNHA-UHFFFAOYSA-N 0.000 claims 1
- IZBOJHBDNMGYCG-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[2,4-dihydro-1h-naphthalene-3,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)CC2=CC=CC=C2CC3)=C1 IZBOJHBDNMGYCG-UHFFFAOYSA-N 0.000 claims 1
- XAUWTHXWHPOJJL-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3,4-dihydrochromene-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(CC2)OC2=CC=CC=C2CC3)=C1 XAUWTHXWHPOJJL-UHFFFAOYSA-N 0.000 claims 1
- XHDXLLZIBXXFME-UHFFFAOYSA-N n-[4-(methylcarbamoyl)pyridin-2-yl]spiro[3h-1-benzofuran-2,4'-piperidine]-1'-carboxamide Chemical compound CNC(=O)C1=CC=NC(NC(=O)N2CCC3(OC4=CC=CC=C4C3)CC2)=C1 XHDXLLZIBXXFME-UHFFFAOYSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 0 CCN=C(C)*=*=C Chemical compound CCN=C(C)*=*=C 0.000 description 2
- KRRQDZHUFBVNNZ-UHFFFAOYSA-N CC1=CCNC(C)=N1 Chemical compound CC1=CCNC(C)=N1 KRRQDZHUFBVNNZ-UHFFFAOYSA-N 0.000 description 1
- NNHJAGVJGIPACA-UHFFFAOYSA-N CCC(C1)C1(F)F Chemical compound CCC(C1)C1(F)F NNHJAGVJGIPACA-UHFFFAOYSA-N 0.000 description 1
- PDUJPCBHGQMGIR-UHFFFAOYSA-N CCC(C1)C1F Chemical compound CCC(C1)C1F PDUJPCBHGQMGIR-UHFFFAOYSA-N 0.000 description 1
- BKUQVCVAPOWJLW-UHFFFAOYSA-N CCC1(CC1)C(F)(F)F Chemical compound CCC1(CC1)C(F)(F)F BKUQVCVAPOWJLW-UHFFFAOYSA-N 0.000 description 1
- IYPJIFIEFDIOEM-UHFFFAOYSA-N CCC1(CC1)F Chemical compound CCC1(CC1)F IYPJIFIEFDIOEM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16555309P | 2009-04-01 | 2009-04-01 | |
| US61/165,553 | 2009-04-01 | ||
| PCT/EP2010/054234 WO2010112520A1 (en) | 2009-04-01 | 2010-03-30 | Spiro derivatives for the modulation of stearoyl-coa desaturase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012522748A JP2012522748A (ja) | 2012-09-27 |
| JP2012522748A5 true JP2012522748A5 (enExample) | 2013-05-16 |
Family
ID=42224469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012502648A Withdrawn JP2012522748A (ja) | 2009-04-01 | 2010-03-30 | ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120010135A1 (enExample) |
| EP (1) | EP2414366A1 (enExample) |
| JP (1) | JP2012522748A (enExample) |
| CN (1) | CN102388052A (enExample) |
| WO (1) | WO2010112520A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014004426A (es) | 2011-10-15 | 2014-07-09 | Genentech Inc | Metodos de uso de antagonistas de scd1. |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| CN105503725B (zh) * | 2015-12-30 | 2018-03-27 | 天津药明康德新药开发有限公司 | 一种叔丁基1‑羟基‑8‑氮杂螺烷[4,5]葵烷‑8‑羧酸酯的制备方法 |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| CA3049010A1 (en) | 2017-01-06 | 2018-07-12 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| ES2909086T3 (es) | 2017-01-11 | 2022-05-05 | Alkermes Inc | Inhibidores bicíclicos de histona desacetilasa |
| SG11202000970WA (en) | 2017-08-07 | 2020-02-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3094527A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CN116003321A (zh) * | 2018-05-09 | 2023-04-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US20250381176A1 (en) * | 2022-06-28 | 2025-12-18 | Modulation Therapeutics, Inc. | Scd1 inhibitors for treating liver disease |
| WO2025018978A1 (en) * | 2023-07-14 | 2025-01-23 | Modulation Therapeutics, Inc. | Scd1 inhibitors for treating hematolymphoid neoplasms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| AU7726600A (en) | 1999-09-28 | 2001-04-30 | Bayer Corporation | Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use |
| PT1315831E (pt) | 2000-02-24 | 2010-11-04 | Xenon Pharmaceuticals Inc | Estearoil-coa dessaturase para identificar agentes terapêuticos que reduzem triglicéridos |
| CA2423885A1 (en) | 2000-09-29 | 2003-03-27 | Shionogi & Co., Ltd. | Thiazole and oxazole derivatives |
| JP4782008B2 (ja) * | 2003-07-30 | 2011-09-28 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリジル誘導体および治療剤としてのその用途 |
| JP2009507791A (ja) * | 2005-08-29 | 2009-02-26 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法 |
| WO2009037542A2 (en) * | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
| WO2010103381A1 (en) * | 2009-03-13 | 2010-09-16 | Glenmark Pharmaceuticals S.A. | Spirocyclic piperidine derivatives as trpm 8 modulators |
-
2010
- 2010-03-30 EP EP10712932A patent/EP2414366A1/en not_active Withdrawn
- 2010-03-30 WO PCT/EP2010/054234 patent/WO2010112520A1/en not_active Ceased
- 2010-03-30 JP JP2012502648A patent/JP2012522748A/ja not_active Withdrawn
- 2010-03-30 US US13/258,121 patent/US20120010135A1/en not_active Abandoned
- 2010-03-30 CN CN2010800149196A patent/CN102388052A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11207325B2 (en) | Triazolopyrimidine compounds and uses thereof | |
| US12012395B2 (en) | Pyridazinone compounds and uses thereof | |
| US10676479B2 (en) | Imidazolepyridine compounds and uses thereof | |
| RU2009114857A (ru) | Гетероциклические органические соединения | |
| TW201831464A (zh) | 作為激酶抑制劑之雜環醯胺 | |
| TWI803600B (zh) | 新穎的三唑酮衍生物或其鹽及包含彼等之醫藥組合物 | |
| JP2012532931A5 (enExample) | ||
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| JP2005509038A5 (enExample) | ||
| US20070142369A1 (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
| US20190375708A1 (en) | Hepatitis b capsid assembly modulators | |
| CA2325069A1 (en) | Use of corticotropin releasing factor antagonists and related compositions | |
| TW200524934A (en) | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | |
| TW200908969A (en) | Organic compounds | |
| SI2933252T1 (en) | Kinase inhibitors as apoptotic signal regulators | |
| KR102589213B1 (ko) | 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제 | |
| JP2008513514A5 (enExample) | ||
| CA2597067A1 (en) | Use of an scd-1 inhibitor to reduce adverse weight gain arising from drug therapy | |
| US20130096149A1 (en) | Heteroaryl compounds and compositions as protein kinase inhibitors | |
| JP2012515787A5 (enExample) | ||
| JP2012515788A5 (enExample) | ||
| JP2019522049A (ja) | トリアゾロピリジン化合物及びその使用 | |
| JP2018508553A5 (enExample) | ||
| JP2025529311A (ja) | 金属チャネル活性化剤を含む併用療法 | |
| JP2013536233A5 (enExample) |